{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:27:46Z","timestamp":1750793266825,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s11255-020-02676-8","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T05:02:43Z","timestamp":1602738163000},"page":"591-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis"],"prefix":"10.1007","volume":"53","author":[{"given":"Louis","family":"Mani\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Noble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Terrec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza Naciri","family":"Bennani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloi","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Janbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphaele","family":"Germi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Bugnazet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farida","family":"Imerzoukene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Malvezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-7286","authenticated-orcid":false,"given":"Lionel","family":"Rostaing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"2676_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/j.ajkd.2011.04.010","volume":"58","author":"K De Keyzer","year":"2011","unstructured":"De Keyzer K, Van Laecke S, Peeters P, Vanholder R (2011) Human cytomegalovirus and kidney transplantation: a clinician\u2019s update. Am J Kidney Dis 58:118\u2013126. https:\/\/doi.org\/10.1053\/j.ajkd.2011.04.010","journal-title":"Am J Kidney Dis"},{"key":"2676_CR2","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/S0140-6736(05)66553-1","volume":"365","author":"EM Hodson","year":"2005","unstructured":"Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, Vimalachandra D, Craig JC (2005) Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365:2105\u20132115. https:\/\/doi.org\/10.1016\/S0140-6736(05)66553-1","journal-title":"Lancet"},{"issue":"Suppl 4","key":"2676_CR3","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1111\/j.1600-6143.2009.02897.x","volume":"9","author":"A Humar","year":"2009","unstructured":"Humar A, Snydman D, AST Infectious Diseases Community of Practice (2009) Cytomegalovirus in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S78\u201386. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02897.x","journal-title":"Am J Transplant"},{"key":"2676_CR4","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A (2018) TheThirdInternationalConsensusGuidelinesonthemanagementof cytomegalovirusinsolid-organtransplantation. Transplantation 102:900\u2013931. https:\/\/doi.org\/10.1097\/TP.0000000000002191","journal-title":"Transplantation"},{"key":"2676_CR5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/tri.12629","volume":"28","author":"T Fehr","year":"2015","unstructured":"Fehr T, Cipp\u00e0 PE, Mueller NJ (2015) Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy? Transpl Int 28:1351\u20131356. https:\/\/doi.org\/10.1111\/tri.12629","journal-title":"Transpl Int"},{"key":"2676_CR6","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","volume":"10","author":"A Humar","year":"2010","unstructured":"Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P (2010) The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10:1228\u20131237. https:\/\/doi.org\/10.1111\/j.1600-6143.2010.03074.x","journal-title":"Am J Transplant"},{"key":"2676_CR7","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1086\/528718","volume":"46","author":"SK Arthurs","year":"2008","unstructured":"Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR (2008) Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 46:840\u2013846. https:\/\/doi.org\/10.1086\/528718","journal-title":"Clin Infect Dis"},{"key":"2676_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/cid\/cit945","volume":"58","author":"DF Florescu","year":"2014","unstructured":"Florescu DF, Qiu F, Schmidt CM, Kalil AC (2014) A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis 58:785\u2013803. https:\/\/doi.org\/10.1093\/cid\/cit945","journal-title":"Clin Infect Dis"},{"key":"2676_CR9","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","volume":"10","author":"H Tedesco Silva Jr","year":"2010","unstructured":"Tedesco Silva Jr H, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, Walker R, Wang Z, Zibari G, Kim YS (2010) Everolimusplusreduced-exposureCsAversusmycophenolicacidplusstandard- exposureCsAinrenal-transplantrecipients. Am J Transplant 10:1401\u20131413. https:\/\/doi.org\/10.1111\/j.1600-6143.2010.03129.x","journal-title":"Am J Transplant"},{"key":"2676_CR10","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1111\/ajt.13327","volume":"15","author":"H Tedesco-Silva","year":"2015","unstructured":"Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-De Lima M, Franco M, Medina-Pestana J (2015) Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant 15:2655\u20132664. https:\/\/doi.org\/10.1111\/ajt.13327","journal-title":"Am J Transplant"},{"key":"2676_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/ajt.14090","volume":"17","author":"Y Qazi","year":"2017","unstructured":"Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S (2017) Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant 17:1358\u20131369. https:\/\/doi.org\/10.1111\/ajt.14090","journal-title":"Am J Transplant"},{"key":"2676_CR12","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1681\/ASN.2018010009","volume":"29","author":"J Pascual","year":"2018","unstructured":"Pascual J, Berger SP, Witzke O et al (2018) Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol 29:1979\u20131991. https:\/\/doi.org\/10.1681\/ASN.2018010009","journal-title":"J Am Soc Nephrol"},{"key":"2676_CR13","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/ajt.15480","volume":"19","author":"SP Berger","year":"2019","unstructured":"Berger SP, Sommerer C, Witzke O et al (2019) Two-year outcomes in de novo renal transplant recipients receiving everolimus\u2014facilitated calcineurin inhibitor reduction regimen from TRANSFORM study. Am J Transplant 19:3018\u20133034. https:\/\/doi.org\/10.1111\/ajt.15480","journal-title":"Am J Transplant"},{"key":"2676_CR14","doi-asserted-by":"publisher","first-page":"11030","DOI":"10.1128\/JVI.78.20.11030-11039.2004","volume":"78","author":"SB Kudchodkar","year":"2004","unstructured":"Kudchodkar SB, Yu Y, Maguire TG, Alwine JC (2004) Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol 78:11030\u201311039. https:\/\/doi.org\/10.1128\/JVI.78.20.11030-11039.2004","journal-title":"J Virol"},{"key":"2676_CR15","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1111\/j.1600-6143.2011.03636.x","volume":"11","author":"G Gerna","year":"2011","unstructured":"Gerna G, Lilleri D, Chiesa A, Zelini P, Furione M, Comolli G, Pellegrini C, Sarchi E, Migotto C, Bonora MR, Meloni F, Arbustini E (2011) Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant 11:2463\u20132471. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03636.x","journal-title":"Am J Transplant"},{"key":"2676_CR16","doi-asserted-by":"publisher","first-page":"e12846","DOI":"10.1111\/tid.12846","volume":"20","author":"A Devresse","year":"2018","unstructured":"Devresse A, Leruez-Ville M, Scemia A et al (2018) Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus. Transpl Infect Dis 20:e12846. https:\/\/doi.org\/10.1111\/tid.12846","journal-title":"Transpl Infect Dis"},{"key":"2676_CR17","doi-asserted-by":"publisher","first-page":"e12907","DOI":"10.1111\/tid.12907","volume":"20","author":"MP Cristelli","year":"2018","unstructured":"Cristelli MP, Esmeraldo RM, Pinto CM et al (2018) The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+\/R-) kidney transplant recipients. Transpl Infect Dis 20:e12907. https:\/\/doi.org\/10.1111\/tid.12907","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"2676_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD (2017) Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum (2017) definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 64(1):87\u201391. https:\/\/doi.org\/10.1093\/cid\/ciw668","journal-title":"Clin Infect Dis"},{"key":"2676_CR19","doi-asserted-by":"publisher","first-page":"e12919","DOI":"10.1111\/tid.12919","volume":"20","author":"G Basso","year":"2018","unstructured":"Basso G, Felipe CR, Cristelli MP et al (2018) The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis. Transpl Infect Dis 20:e12919. https:\/\/doi.org\/10.1111\/tid.12919","journal-title":"Transpl Infect Dis"},{"key":"2676_CR20","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","volume":"11","author":"DC Brennan","year":"2011","unstructured":"Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS (2011) Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 11:2453\u20132462. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03674.x","journal-title":"Am J Transplant"},{"key":"2676_CR21","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1111\/ajt.14215","volume":"17","author":"F Shihab","year":"2017","unstructured":"Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi VR, Shaffer D (2017) Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus. Am J Transplant 17:2363\u20132371. https:\/\/doi.org\/10.1111\/ajt.14215","journal-title":"Am J Transplant"},{"key":"2676_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.6002\/ect.2016.0234","volume":"16","author":"Z Mithani","year":"2018","unstructured":"Mithani Z, Gralla J, Adebiyi O, Klem P, Cooper JE, Wiseman AC (2018) De novo donor-specific antibody formation in tacrolimus-based, mycophenolate versus mammalian target of rapamycin immunosuppressive regimens. Exp Clin Transplant 16:23\u201330. https:\/\/doi.org\/10.6002\/ect.2016.0234","journal-title":"Exp Clin Transplant"},{"key":"2676_CR23","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1097\/TP.0000000000001693","volume":"102","author":"A Kurdi","year":"2018","unstructured":"Kurdi A, Martinet W, De Meyer GRY (2018) mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis. Transplantation 102:S44\u2013S46. https:\/\/doi.org\/10.1097\/TP.0000000000001693","journal-title":"Transplantation"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02676-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-020-02676-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02676-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T09:06:09Z","timestamp":1634288769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-020-02676-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["2676"],"URL":"https:\/\/doi.org\/10.1007\/s11255-020-02676-8","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"type":"print","value":"0301-1623"},{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"10 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}